Foxo4 Peptide

Foxo4 Peptide
Paub meej:
CAS Nr .: 2460055-10-9
Cov tsos mob: Dawb crystalline hmoov
MF: C228H388N86O64
wb: 5358
Specifications: Raw hmoov los yog vials daim ntawv
Purity: NLT 99.12%
Solubility: Soluble hauv dej
Customization Service: Negotiable; daim ntawv lo, vials loj, thiab mg rau ib lub vial tuaj yeem kho tau. Tab sis peb tsuas yog lees txais kev txiav txim rau kev tshawb fawb.
Xa kev nug
Hauj lwm lawm
Xa kev nug

FOXO4 peptide hmoovyog ib chav kawm ntawm cov protein-protein interaction (PPI)-interfering peptides tsim los ntawm FOXO4-p53 kev sib cuam tshuam kev sib tshuam, siv los ua cov ntaub ntawv tshawb fawb rau kev xaiv tshem tawm ntawm cov hlwb senescent.

Qhov tsim qauv tsim nyog yog txhawm rau sib tw thaiv FOXO4-p53 khi, tshem tawm cov ciaj sia taus ntawm cov hlwb senescent ntawm qhov complex; Qhov no txhawb nqa p53 xa tawm los ntawm lub nucleus thiab ua kom lub cev mitochondrial apoptotic signaling, yog li ua tiav kev xaiv tua ntawm cov hlwb senescent.

Shaanxi Medibridge muab FOXO4 raw hmoov ntawm tsis pub tsawg tshaj 99.12% purity, txheeb xyuas los ntawm HPLC/MS. Raws li peptide cov khoom siv raw khoom lag luam ua haujlwm raws li GMP Kev Tswj Xyuas Cov Qauv, peb ua kom zoo ib yam, tag nrho cov khoom siv taug qab, thiab lub sijhawm ua haujlwm tau zoo. Txhua lub nkoj xa nrog COA thiab ua tiav cov ntaub ntawv. Kev cai specifications thiab scale-up yog muaj nyob rau ntawm kev thov. Kev ntseeg siab thoob ntiaj teb logistics thiab kev txhawb nqa kev pabcuam pab ua kom koj txoj kev tshawb fawb txav mus.

FOXO4 peptide

 

 

COA

 

product-833-138

Khoom npe

CAS Nr

Batch Number

FOXO4-DRI

2460055-10-9

MB2511031928

Hnub tim tsim khoom

Hnub Soj Ntsuam

Hnub Kawg

2025-11-03

2025-11-04

2027-11-01

Qauv Qty Base

Ntim

Txoj Kev Xeem

58.32 Nws

5GS / lub raj mis

HPLC

 

Yam khoom

Txuj

Cov txiaj ntsig

Purity

Ntau dua lossis sib npaug li 98%

99.12%

Peptide Assay

Ntau dua lossis sib npaug li 80%

83.19%

Loj Spectrum

5358

5358

Solubility

Soluble hauv dej

Ua raws

Clarity thiab xim ntawm kev daws

Ntshiab thiab tsis muaj xim

Ua raws

Sodium ntsev

<5.0%

2.14%

Dej

Tsawg dua lossis sib npaug li 7.0%

3.62%

Residual Solvent:

 

Methanol

Tsawg dua lossis sib npaug li 0.3%

Ua raws

Isopropanol

Tsawg dua los yog sib npaug li 0.5%

0.158%

Cov tshuaj acetonitrile

Tsawg dua lossis sib npaug li 0.041%

0.019%

Methylene Chloride

Tsawg dua lossis sib npaug li 0.06%

0.028%

N,N{0}}Dimethylformamide

Tsawg dua lossis sib npaug li 0.088%

Ua raws

Triethylamine

Tsawg dua lossis sib npaug li 0.032%

Ua raws

Tert -butyl methyl ether

Tsawg dua los yog sib npaug li 0.5%

0.179%

Endotoxin

Tsawg dua lossis sib npaug li 0.5 EU / mg

Ua raws

Microbial txwv

Tag nrho cov kab mob aerobic<100 CFU/g

Tag nrho cov poov xab & pwm<50 CFU/g

<50 CFU/g

<10 CFU/g

Cia

Khaws rau hauv qhov chaw tsaus thiab txias qhuav (-20 txog 8 degree)

Xaus

Cov batch ua raws li IN-HOUSE tus qauv

product-907-160

 

 

Peb qhov zoo

 

1. Purity Ntau dua lossis sib npaug li 99.12%, HPLC/MS dual tso tawm.

2. GMP tswj qhov system ntau lawm, siab batch - mus rau -batch sib xws, tag nrho traceability.

3. Ua kom tiav cov ntaub ntawv zoo: CoA, HPLC/MS chromatograms, residual solvent thiab ntsev hom ntawv qhia.

4. Kev hloov kho yooj yim: Ib ntus / hom ntsev (TFA thiab acetate tshem tawm), scale- nce.

5. Kev xa khoom ruaj khov: Lyophilized hmoov, qis - kub thiab lub teeb - ntim tiv thaiv, tswj lub sijhawm xa khoom.

6. Kev txhawb nqa kev tshaj lij: Kev faib tawm thiab kev npaj cov txheej txheem, kev sib tham hauv daim ntawv thov, thiab tom qab - kev muag khoom.

 

Daim ntawv

Qauv Order

Specification

Cov hmoov nyoos

1 g

Purity yog NLT 99.12%

Vials

10 vials

3ml / 5ml / 7ml / 15ml vials thiab lwm yam.

 

 

Mechanism ntawm Action

Upstream triggers thiab FOXO4 tsub zuj zuj

Senescence- cuam tshuam nrog kev ntxhov siab (DNA puas tsuaj, telomere shortening, oxidative stress) qhib DDR → p53–p21 axis thiab tswj kev loj hlob. Nyob rau hauv parallel, FOXO4 kev qhia / kev ruaj ntseg thiab nuclear localization yog upregulated, nrog sustained residency nyob rau hauv senescent hlwb, teem rau theem tom ntej ruaj khov complex tsim nrog p53.

 

Lub luag haujlwm lom ntawm FOXO4-p53 complex

Hauv cov hlwb senescent, FOXO4 tsim ib txoj hauv kev nrog p53 uas txhawb nqa p53 lub nuclear retention, steering nws mus rau ib tug transcriptional kev pab cuam uas txhawb nqa ntes thiab ciaj sia taus (xws li, p21) thaum suppressing nws mitochondrial pro-apoptotic muaj nuj nqi. Ua haujlwm zoo, qhov kev ua haujlwm no yog qhov kev txhawb nqa uas khaws cia lub xeev ruaj khov thiab tiv thaiv apoptosis.

FOXO4 peptide supplier

Kev khi qhov chaw thiab conformational logic ntawm interfering peptide

CovFOXO4 peptide hmoovyog muab los ntawm qhov tseem ceeb ntawm FOXO4-p53 kev tiv tauj cheeb tsam thiab siv D-retro-inverso (DRI) tsim los khaws cia sab-chain orientation thaum ua kom muaj zog tiv thaiv proteolysis. Nws muaj kev sib tw occupies lub binding interface, yog li tsis muaj zog los yog dismantling lub endogenous FOXO4-p53 complex.

 

Pib ntawm txoj kev mitochondrial

Thaum tso tawm los ntawm kev tuav pov hwm nuclear, p53 koom nrog BCL-2 cov neeg hauv tsev neeg ntawm cytosol / mitochondrial nto, ua kom muaj kev sib haum xeeb ntawm BAX / BAK thiab mitochondrial txheej membrane permeabilization (MOMP). Cytochrome c yog ces tso tawm thiab lub caspase cascade yog qhib, yielding xaiv apoptosis ntawm senescent hlwb.

FOXO4 raw powder

 

 

Molecular Design thiab Physicochemical Properties

D-retro-inverso (DRI) lub tswv yim

Cov qib peptide yog thim rov qab thiab tsim los ntawm D-amino acids; Sab-chain spatial orientation ua raws li haiv neeg L-peptide, thaum ua kom muaj zog tiv thaiv proteolysis thiab hauv vivo persistence.

 

Cellular nkag

Feem ntau ua tiav los ntawm kev sib xyaw CPP ntawm N- lossis C-terminus (xws li, TAT-hom lossis lwm yam polybasic ntu) txhawm rau txhim kho endocytosis / kev thauj mus los.

 

Solubility thiab isoelectric point

Enriched nyob rau hauv yooj yim residues, feem ntau weakly yooj yim nrog nruab nrab hydrophilicity; feem ntau yaj hauv cov dej tsis huv, PBS, lossis cov buffers uas muaj me me ntawm DMSO (ib qho me me ntawm cov polar co-solvent yuav muab ntxiv yog tias xav tau).

 

Kev tsim qauv

Feem ntau muab raws li lyophilized hmoov, dosed los ntawm net peptide cov ntsiab lus; Feem ntau muab raws li TFA lossis acetate ntsev (TFA ntau dhau tuaj yeem ua rau muaj keeb kwm yav dhau los cytotoxicity-xav tau cov ntsev acetate lossis ua TFA tshem tawm).

peptide supplier

 

 

Piv nrog rau lwm yam "Kev laus tshem tawm" tswv yim

 

Mus cuag

Piv txwv

Pros

Cons

BCL 2 tsev neeg inhibitors

Navitoclax

Kev ua haujlwm ntawm senolytic dav

Dose limiting platelet toxicity

Natural khoom combos

Dasatinib + quercetin; fisetin

Qhov ncauj, nkag tau

Variable selectivity; batch variability

Immuno cov tswv yim

Cov kab mob oncolytic; CAR T/cov tshuaj tiv thaiv

Muaj peev xwm ruaj ruaj clearance

High complexity thiab nqi

p16/p21 axis phiaj

Synthetic biology; PROTAC; molecular kua nplaum

High precision

Kev tshawb nrhiav thaum ntxov

 

 

 

Cov ntsiab lus tseem ceeb ntawm kev sim tsim qauv thiab cov kev tswj xyuas tseem ceeb

 

peptide factory

 

Cov qauv no tsuas yog muab rau kev tshawb fawb / kev sib pauv kev kawm.

 

Tswj

Ua ke cov hlwb uas tsis yog-senescent counterpart los txheeb xyuas cov kev xaiv ntau dua li cov cytotoxicity.

Scrambled-sequence peptide raws li kev tswj tsis zoo; match net peptide cov ntsiab lus thiab ntsev daim ntawv.

p53-txheej xwm tswj: p53 inhibitor, knockdown, los yog mutant qauv los qhia p53 dependence.

CPP-tsuas yog kev tswj xyuas los soj ntsuam ib qho kev cuam tshuam hauv lub cev rau ntu ntawm tes nkag mus.

 

Dose thiab lub sij hawm optimization

Ntsuas 0.5-20 μM concentration ntau thiab 24-96 teev lub sij hawm los txheeb xyuas qhov kev xaiv dav tshaj plaws (muaj zog tua cov hlwb uas muaj kev cuam tshuam tsawg rau cov hlwb uas tsis yog senescent).

 

Kev txhais cov ntaub ntawv

Siv senolysis selectivity ua thawj qhov kawg; xam ib qho kev ntsuas kev xaiv (xws li, tsis yog-senescent viability / senescent viability nyob rau hauv cov xwm txheej zoo ib yam, lossis EC50 piv).

 

Tsis txhob xaus lus los ntawm SA-gal ib leeg; suav nrog apoptosis nyeem ntawv thiab SASP cov cim yam tsawg kawg nkaus.

 

Yog tias tsuas yog pom qhov hloov pauv SASP ib ntus xwb, xav txog lub sijhawm ua piv txwv cov ntsiab lus kom zoo (thaum ntxov apoptotic kev ntxhov siab tuaj yeem ua rau luv luv inflammatory yam ua ntej lawv poob).

 

 

 

FAQ

 

Q: Yuav ua li cas reconstitute thiab npaj?

A: Siv cov dej tsis huv lossis PBS nyiam, nrog me me ntawm DMSO / polar solubilizer yog tias tsim nyog. Qhov kawg concentration rau kev sim ntawm tes yuav tsum tsawg dua lossis sib npaug li 0.1–0.2%.

Q: Pom zoo siv tej yam kev mob?

A: Nyob rau hauv vitro thawj gradient: 0.5-20 μM, incubation lub sij hawm: 24-96 h, optimized nyob ib ncig ntawm lub "selectivity window"; ntau npaum li cas yuav tsum tau txiav txim raws li qauv ua ntej- kev sim (rau kev tshawb fawb nkaus xwb).

Q: Puas yog Shaanxi Medibridge cov chaw tsim khoom ntawm Adipotide?

A: Yog lawm, peb tsis tsuas yog muab adipotide nrog purity tsis tsawg dua 99%, tab sis Shaanxi Medibridge Biotech Co., Ltd. kuj yog tus xa khoom peptide.

Q: Koj puas tuaj yeem lav qhov purity?

A: Tau kawg, peb tuaj yeem lav tias qhov purity ntawm peb cov khoom tsis muaj tsawg dua 99%.

 

Xav tau ib lub chaw tsim tshuaj paus rau GLP-1/Dual (GLP-1/GIP) thiabFOXO4 peptide hmoov? Peb ua haujlwm raws li GMP kev tswj hwm, muab kev tshawb fawb-siv-tsuas cov ntaub ntawv nrog COAs pob tshab, muaj zog ntau-rau-ntau sib xws, thiab kev txhawb nqa sai. Rau cov lus hais, lub sijhawm ua, lossis kev cai tshwj xeeb, hu rau hi@medibridgeapi.com lossis WhatsApp +44 07548632075.

 

Cim npe nrov: Tuam Tshoj foxo4 peptide manufacturers, lwm tus neeg, Hoobkas

Xa kev nug